Harrow Health (HROW) Set to Announce Earnings on Monday

Harrow Health (NASDAQ:HROW - Get Free Report) is scheduled to release its earnings data after the market closes on Monday, May 13th. Analysts expect Harrow Health to post earnings of ($0.25) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Harrow Health (NASDAQ:HROW - Get Free Report) last released its earnings results on Tuesday, March 19th. The company reported ($0.27) earnings per share (EPS) for the quarter. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. The company had revenue of $36.36 million during the quarter, compared to analysts' expectations of $37.65 million. On average, analysts expect Harrow Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Harrow Health Stock Up 1.1 %

NASDAQ HROW traded up $0.11 during trading hours on Monday, hitting $10.49. 194,654 shares of the company were exchanged, compared to its average volume of 434,657. The company has a 50 day moving average of $11.45 and a two-hundred day moving average of $10.97. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60. The firm has a market cap of $371.14 million, a price-to-earnings ratio of -13.99 and a beta of 0.58. Harrow Health has a 52-week low of $7.60 and a 52-week high of $28.25.

Insider Buying and Selling

In other Harrow Health news, major shareholder Opaleye Management Inc. bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, April 25th. The stock was purchased at an average price of $9.97 per share, for a total transaction of $199,400.00. Following the completion of the purchase, the insider now directly owns 3,815,000 shares in the company, valued at $38,035,550. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Mark L. Baum purchased 9,000 shares of the company's stock in a transaction dated Friday, March 22nd. The stock was acquired at an average price of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the transaction, the chief executive officer now directly owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Opaleye Management Inc. purchased 20,000 shares of the company's stock in a transaction dated Thursday, April 25th. The stock was purchased at an average price of $9.97 per share, with a total value of $199,400.00. Following the transaction, the insider now owns 3,815,000 shares of the company's stock, valued at $38,035,550. The disclosure for this purchase can be found here. Insiders acquired a total of 170,715 shares of company stock worth $1,864,011 over the last 90 days. 13.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HROW has been the topic of several analyst reports. B. Riley reduced their target price on shares of Harrow Health from $30.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, March 22nd. Craig Hallum assumed coverage on shares of Harrow Health in a research report on Thursday, April 11th. They set a "buy" rating and a $24.00 price objective for the company.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.